公司资料
Alvotech 股价、新闻与催化剂
- 股票代码:
- ALVO
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Iceland
股票表现
5.62 USD (-3.10%)
收盘价
最后更新: 2026年10月1日
936M USD
市值
股价为何变动
最新监测到的公司动态为“Matvæla- og lyfjastofnun Bandaríkjanna (FDA) veitir viðbótarleyfi fyrir framleiðslu á hliðstæðunni við Humira í báðum framleiðslueiningum lyfjaverksmiðju Alvotech í Reykjavík”。相应的收盘价反应尚未产生。
公司概览
Global Biosimilar Developer and Manufacturer
Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines. It operates an integrated model covering cell-line development, process development, clinical studies, regulatory submissions, commercial-scale manufacturing, and supply to regional marketing partners.
Commercial Biosimilar Portfolio
The marketed portfolio includes biosimilars referencing Humira and Stelara, providing exposure to large immunology markets. Additional products referencing Prolia/Xgeva, Simponi/Simponi Aria, and Eylea broaden the portfolio into bone disease and ophthalmology.
Global Partnership Model
Alvotech generally partners with regional pharmaceutical companies for commercialization while retaining responsibility for development and manufacturing. This structure gives the company access to many markets without building a fully owned sales organization in every country.
Manufacturing-Centered Strategy
Complex biologic manufacturing is a core competitive capability. Alvotech's facilities support development through commercial supply, and regulatory inspections, manufacturing readiness, and reliable scale-up are critical to both product approvals and partner launches.
Expanding Late-Stage Pipeline
The pipeline includes AVT03, AVT05, AVT06, AVT16, AVT80, and additional biosimilars targeting high-value biologics across immunology, ophthalmology, oncology, and other specialty markets. Multiple candidates are being reviewed across the United States, Europe, and additional international jurisdictions.
未来催化剂
- FDA regulatory decisions in the fourth quarter of 2026 for resubmitted applications covering AVT03, AVT05, and AVT06.
- Regulatory decisions for additional late-stage biosimilars AVT16 and AVT80 following ongoing U.S. and European reviews.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。